Targeted Genetics to Present at the Acumen BioFin Rodman &Amp; Renshaw 4th Annual Global Healthcare Conference
Posted on: Thursday, 10 May 2007, 09:00 CDT
Targeted Genetics Corporation (NASDAQ: TGEN) announced today that H. Stewart Parker, President and Chief Executive Officer, will present a company overview at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference on Monday, May 14 at 9:25 a.m., Monte Carlo, Monaco.
The presentation will be webcast live and available for replay from the Targeted Genetics website, www.targetedgenetics.com. A link to connect to the webcast will be under the "Events" section of the Company's homepage.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit Targeted Genetics' website at www.targetedgenetics.com.
Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392
SOURCE: Targeted Genetics
Source: MARKET WIRE
Related Articles
- Targeted Genetics Corporation Recommended for Up to $2.4 Million in Funding By Department of Defense
- Targeted Genetics Presents Additional Data From Its Inflammatory Arthritis Program at the 13th Annual Congress of the European Society of Gene Therapy
- Targeted Genetics to Present At 2005 BIO InvestorForum
- Targeted Genetics Initiates Next Clinical Trial of tgAAC94 in Inflammatory Arthritis
- Targeted Genetics to Present at Roth Capital Partners New York Conference
- Targeted Genetics Announces Issuance of Additional Adeno-Associated Virus (AAV) Vector Technology Patent
- Targeted Genetics Announces Todd E. Simpson to Step Down As Chief Financial Officer
- Targeted Genetics Strengthens Intellectual Property for AAV Vector Manufacturing
- Targeted Genetics Reports Second Quarter Financial Results
- Targeted Genetics Announces Preliminary Results of Phase I Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis
 |
 |
User Comments (0)
RSS Feeds